Wockhardt has received approval from the Central Drugs Standard Control Organisation (CDSCO) for the import and marketing of its novel antibiotic, Zaynich (Zidebactam/Cefepime), in India. The drug is designed to treat complicated urinary tract infections and Gram-negative bacteremia, offering a new solution against drug-resistant bacteria.
The approval is supported by the ENHANCE-1 Phase 3 clinical trial, which demonstrated that 89% of patients treated with Zaynich achieved clinical cure and microbiological eradication, compared to 68.4% in the Meropenem group. This represents a significant treatment advantage of 20.6%.
In high-risk bacteremia patients, Zaynich showed an 89% response rate, significantly outperforming Meropenem's 44%. This highlights Zaynich's potential as a transformative therapy for severe drug-resistant infections.
Wockhardt's shares have seen a remarkable increase, surging nearly 27% in the past month and 946% over the last three years. The company's market capitalisation now stands at approximately Rs 28,777 crore.
Technical indicators suggest that Wockhardt's stock is currently overbought, with a 14-day Relative Strength Index (RSI) of 72.3. However, the stock remains above all key simple moving averages, indicating strong momentum.
Background
Wockhardt's development of Zaynich marks a significant step in combating antibiotic resistance, particularly against carbapenem-resistant infections. This approval could position the company as a leader in addressing one of India's most pressing healthcare challenges.
Looking ahead, investors will be watching how Wockhardt leverages this approval to expand its market presence and address the growing issue of antibiotic resistance in India.
